NEW Research—New triple antiviral drug therapy of interferon beta-1b, lopinavir-ritonavir, and ribavirin shows early promise for treating #COVID19 in phase 2 randomised trial; but large phase 3 studies in critically ill patients are neededhttps://t.co/1mZwt7wsMl pic.twitter.com/M5IWvzThOp

— The Lancet (@TheLancet) May 8, 2020